Company: XAIR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001493152-25-005678
Chunk: 67

Company: Beyond Air, Inc.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 1
Chunk 67
---
31, 2023. The decrease of $3.8 million was primarily attributed to a decrease in spend in salaries $0.8 million ($0.6
million in Beyond Air and of $0.2 million in Beyond Cancer), stock-based compensation $2.2 million  in Beyond Cancer, pre-clinical studies $0.5 million ($0.4 million in Beyond Air and $0.1 million in Beyond Cancer), clinical
studies $0.9 million ($0.6 million in Beyond Air and $0.3 million in Beyond Cancer), professional fees $0.1 million in Beyond Air offset
by an increase in Gen II device development costs of $0.7 million in Beyond Air.

Research
and development expenses for the nine months ended December 31, 2024 were $13.6 million as compared to $18.7 million for the nine months
ended December 31, 2023. The decrease of $5.1 million was primarily attributed to a decrease in spend in salaries $0.5 million ($1.0
million in Beyond Air offset by an increase of $0.5 million restructuring costs in Beyond Cancer), stock-based compensation $3.7 million
($0.8 million in Beyond Air and $2.9 million in Beyond Cancer), pre-clinical studies $1.0 million ($0.9 million in Beyond Air and $0.1
million in Beyond Cancer), clinical studies $1.5 million ($1.1 million in Beyond Air and $0.4 million in Beyond Cancer), professional
fees $0.4 million ($0.2 million in Beyond Air and $0.2 million in Beyond Cancer), travel expenses $0.1 million in Beyond Air offset by
an increase in Gen II device development costs of $2.2 million in Beyond Air.

Selling,
General and Administrative Expenses

Selling,
general and administrative expenses for the three months ended December 31, 2024 and December 31, 2023 were $7.7 million and $9.8 million,
respectively. The decrease of $2.0 million was attributed primarily to a decrease in spend in salaries $0.3 million ($0.5 million in
Beyond Air offset by increased spend of $0.2 million in Beyond Cancer), a decrease of $1.8 million due to stock based compensation cost
($0.3 million in Beyond Air and $1.5 million related to Beyond Cancer), $